Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: maceng2 who wrote (170295)	6/5/2002 4:41:57 AM
From: maceng2	Read Replies (1) \| Respond to of 436258

US drugs giant in breast cancer suit Generic drug campaigners say cheaper pills save lives More than half the states in the United States have brought an anti-trust lawsuit over a breast cancer treatment against giant drug maker Bristol-Myers Squibb. The filing alleges the US-based firm illegally prevented breast cancer suffers from having access to cheaper, generic versions of the drug Taxol. The lawsuit, which seeks unspecified damages, was filed in the US District Court for the District of Columbia. "Bristol made billions off this single drug while untold numbers of women were being denied access to a more affordable treatment," Michigan Attorney General Jennifer Granholm said in a statement. Patent extension Bristol-Myers spokesman Robert Laverty said: "We will continue to deal with the issues raised by this new suit as we have been doing with other litigation related to these matters." The US Food and Drug Administration (FDA) granted Bristol-Myers exclusive marketing rights to Taxol in 1992 for five years. Bristol-Myers later obtained extra patents that protected its exclusive position for another three years until October 2000. The states argue that by doing so it blocked rival firms from developing alternative, generic versions of the drug which would have cost 33% less. "It is morally and legally reprehensible for this country's companies to block competition and overcharge consumers, especially cancer patients," said Ms Granholm. The FDA licensed generic versions of the drug in the autumn of 2000. Yew bark The states have also objected that the active ingredient in Taxol was developed using public funds. Paclitaxel, the compound's active ingredient, was developed by the National Cancer Institute from a substance found in yew tree bark. Bristol-Myers took the drug through clinical trials and brought it to market. Taxol is also used to treat ovarian cancer and other cancers. Bristol-Myers's shares slid 4% on Tuesday to close at $28.65 on the New York Stock Exchange. In recent weeks, Bristol-Myers Squibb has held talks with UK rival GlaxoSmithKline to explore the possibility of a merger to create the world's largest pharmaceutical firm. Analysts estimate a successful tie-up would create a firm worth $190bn (£129.7bn; 202.8bn euros). news.bbc.co.uk